207572-68-7

207572-68-7 structure

Name: Rilmenidine hemifumarate
Chemical Name: Rilmenidine hemifumarate salt
CAS Number: 207572-68-7
Molecular Formula: C₂₄H₃₆N₄O₆
Molecular Weight: 476.566
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2018-08-31 11:02:29
Modify Date: 2024-01-10 21:30:12
Rilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine hemifumarate is an alpha 2-adrenoceptor agonist. Rilmenidine hemifumarate induces autophagy. Rilmenidine hemifumarate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+/H+ antiport. Rilmenidine hemifumarate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells [1][2][3].

Name	Rilmenidine hemifumarate salt
Synonyms	N-(Dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine (2E)-but-2-enedioate (2:1) MFCD00673925 N-(Dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine (2E)-2-butenedioate (2:1) 2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-, (2E)-2-butenedioate (2:1) MFCD09878261

Description	Rilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine hemifumarate is an alpha 2-adrenoceptor agonist. Rilmenidine hemifumarate induces autophagy. Rilmenidine hemifumarate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+/H+ antiport. Rilmenidine hemifumarate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells [1][2][3].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> Imidazoline Receptor Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> Imidazoline Receptor Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor
In Vitro	Rilmenidine provides antihypertensive efficacy comparable with that of diuretics, beta-blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors[1]. Rilmenidine (25-100 μM; 24 hours) inhibits K562 cell proliferation[2]. Cell Viability Assay[2] Cell Line: K562 cells Concentration: 25, 50, 100 μM Incubation Time: 24 hours Result: Dose-dependently inhibited K562 colony formation.
In Vivo	Rilmenidine-treated N171-82Q mice (i.p.; 4-times a week) displays significant improved forelimb grip strength and all limbs grip strength from 12 to 22 weeks of age[3]. Rilmenidine decreases levels of mutant huntingtin[3].
References	[1]. Reid JL. Rilmenidine: a clinical overview. Am J Hypertens. 2000;13(6 Pt 2):106S-111S. [2]. Srdic-Rajic T, et al. Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. Eur J Pharm Sci. 2016;81:172-180. [3]. Reid JL. Rilmenidine: a clinical overview. Am J Hypertens. 2000;13(6 Pt 2):106S-111S. [4]. Rose C, et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet. 2010;19(11):2144-2153.

Molecular Formula	C₂₄H₃₆N₄O₆
Molecular Weight	476.566
Exact Mass	476.263489

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Safety Phrases	S22;S24/25
RIDADR	NONH for all modes of transport
RTECS	RP7207400

207572-68-7	54187-04-1
54249-57-9	85047-14-9
85409-38-7	1621688-31-0
69906-85-0	173334-58-2
1435938-24-1	1369665-02-0